NDAINTRAVENOUSPOWDERPriority Review
Approved
Jul 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
KINEVAC (sincalide) by Bracco. Approved for cholecystokinin analog [epc]. First approved in 1976.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KINEVAC (sincalide) is a cholecystokinin analog administered intravenously as a powder for reconstitution. It stimulates gallbladder contraction and is used primarily in diagnostic imaging to assess biliary tract function. The drug works by mimicking cholecystokinin, a natural hormone that triggers gallbladder emptying.
LOE Approaching
As a mature diagnostic agent approaching loss of exclusivity with low commercial pressure (30 competitive index), expect a lean, specialized team focused on hospital imaging departments rather than growth-stage expansion.
Mechanism of Action
Pharmacologic Class:
Cholecystokinin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying
Started May 2008
60 enrolled
Healthy
Career Relevance
Working on KINEVAC offers limited career growth given its mature, LOE-approaching status and minimal linked job postings. Roles would be highly specialized, focused on maintaining diagnostic imaging partnerships and managing generic competition in a stable but shrinking revenue base.
Hospital Account Manager
Worked on KINEVAC at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.